omeprazole has been researched along with Eosinophilic Esophagitis in 19 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
Eosinophilic Esophagitis: Chronic ESOPHAGITIS characterized by esophageal mucosal EOSINOPHILIA. It is diagnosed when an increase in EOSINOPHILS are present over the entire esophagus. The reflux symptoms fail to respond to PROTON PUMP INHIBITORS treatment, unlike in GASTROESOPHAGEAL REFLUX DISEASE. The symptoms are associated with IgE-mediated hypersensitivity to food or inhalant allergens.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In esophageal cell cultures, omeprazole has been reported to inhibit Th2 cytokine-stimulated expression of eotaxin-3, an eosinophil chemoattractant contributing to esophageal eosinophilia in eosinophilic esophagitis (EoE)." | 7.78 | Omeprazole blocks STAT6 binding to the eotaxin-3 promoter in eosinophilic esophagitis cells. ( Cheng, E; Huo, X; Pham, TH; Souza, RF; Spechler, SJ; Wang, DH; Yu, C; Zhang, Q; Zhang, X, 2012) |
| "Sixty consecutive symptomatic patients with documented oesophageal eosinophilia received open-label omeprazole 20 mg orally twice daily before meals for 8 weeks." | 5.17 | The outcome of patients with oesophageal eosinophilic infiltration after an eight-week trial of a proton pump inhibitor. ( Achem, SR; Devault, KR; Khrisna, M; Ngamruengphong, S; Talley, NJ; Vazquez-Elizondo, G, 2013) |
| "Omeprazole does not inhibit Th2 cytokine-stimulated eotaxin-3 expression by esophageal fibroblasts, suggesting that PPIs will have limited impact on subepithelial EoE processes such as fibrosis." | 3.83 | JAK-STAT6 Pathway Inhibitors Block Eotaxin-3 Secretion by Epithelial Cells and Fibroblasts from Esophageal Eosinophilia Patients: Promising Agents to Improve Inflammation and Prevent Fibrosis in EoE. ( Cheng, E; Huo, X; Park, JY; Souza, RF; Spechler, SJ; Wang, DH; Wilson, KS; Yu, C; Zhang, Q; Zhang, X, 2016) |
| " In esophageal cell cultures, omeprazole has been reported to inhibit Th2 cytokine-stimulated expression of eotaxin-3, an eosinophil chemoattractant contributing to esophageal eosinophilia in eosinophilic esophagitis (EoE)." | 3.78 | Omeprazole blocks STAT6 binding to the eotaxin-3 promoter in eosinophilic esophagitis cells. ( Cheng, E; Huo, X; Pham, TH; Souza, RF; Spechler, SJ; Wang, DH; Yu, C; Zhang, Q; Zhang, X, 2012) |
| " Proton pump inhibitor (PPI) use in EoE does not lead to histologic improvement; however, the long-term use of PPI on symptoms and prevention of complications has not been evaluated." | 2.77 | Conservative long-term treatment of children with eosinophilic esophagitis. ( Edelman, M; Lai, J; Levine, J; Schuval, SJ, 2012) |
| "Although basal cell hyperplasia is a histologic hallmark of eosinophilic esophagitis (EoE), little is known about the capabilities of epithelial renewal and differentiation in the EoE inflammatory milieu." | 1.72 | CD73 ( Aaron, B; Dolinsky, L; Hamilton, KE; Hara, T; Karakasheva, TA; Karami, A; Kasagi, Y; Klein, J; Lynch, K; Maekawa, H; Muir, AB; Nakagawa, H; Nunes, K; Ruffner, MA; Sasaki, M; Shimonosono, M; Shimonosono, R; Spergel, JM; Wang, J; Wei, J; Whelan, KA; Wilkins, B, 2022) |
| "Although the key features of eosinophilic esophagitis have been increasingly described over recent years, this entity is still often not considered and consequently diagnosis is often either not made or delayed." | 1.38 | Eosinophilic esophagitis and food impaction: an instructive case. ( Day, A; Lemberg, D; Tilakaratne, S, 2012) |
| "TREATMEN The contribution of eosinophilic esophagitis (EoE) to refractory gastroesophageal reflux disease (GERD) remains unknown." | 1.37 | Eosinophilic esophagitis in patients with typical gastroesophageal reflux disease symptoms refractory to proton pump inhibitor. ( Barbuti, RC; Eisig, JN; Hashimoto, CL; Kishi, HS; Moraes-Filho, JP; Navarro-Rodriguez, T; Sá, CC; Silva-Werneck, AL, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 14 (73.68) | 24.3611 |
| 2020's | 5 (26.32) | 2.80 |
| Authors | Studies |
|---|---|
| Hara, T | 1 |
| Kasagi, Y | 1 |
| Wang, J | 1 |
| Sasaki, M | 1 |
| Aaron, B | 1 |
| Karami, A | 1 |
| Shimonosono, M | 1 |
| Shimonosono, R | 1 |
| Maekawa, H | 1 |
| Dolinsky, L | 1 |
| Wilkins, B | 1 |
| Klein, J | 1 |
| Wei, J | 1 |
| Nunes, K | 1 |
| Lynch, K | 1 |
| Spergel, JM | 1 |
| Hamilton, KE | 1 |
| Ruffner, MA | 1 |
| Karakasheva, TA | 1 |
| Whelan, KA | 1 |
| Nakagawa, H | 1 |
| Muir, AB | 1 |
| Posner, S | 1 |
| Boyd, A | 1 |
| Patel, A | 1 |
| Torrijos, EG | 1 |
| Gómez, ARG | 1 |
| Ortega, AME | 1 |
| Jimenez, OG | 1 |
| Romo, JBJ | 1 |
| Rodriguez, RG | 1 |
| Rochman, M | 1 |
| Xie, YM | 1 |
| Mack, L | 1 |
| Caldwell, JM | 1 |
| Klingler, AM | 1 |
| Osswald, GA | 1 |
| Azouz, NP | 1 |
| Rothenberg, ME | 1 |
| Odiase, E | 1 |
| Zhang, X | 5 |
| Chang, Y | 1 |
| Nelson, M | 1 |
| Balaji, U | 1 |
| Gu, J | 1 |
| Zhang, Q | 4 |
| Pan, Z | 1 |
| Spechler, SJ | 5 |
| Souza, RF | 5 |
| Gómez Torrijos, E | 1 |
| Donado Palencia, P | 1 |
| Sanchez Miranda, MP | 1 |
| Moreno Lozano, L | 1 |
| Extremera Ortega, AM | 1 |
| Borja Segade, JM | 1 |
| Galindo Bonilla, PA | 1 |
| García Rodríguez, R | 1 |
| Lieberman, JA | 1 |
| Vazquez-Elizondo, G | 1 |
| Ngamruengphong, S | 1 |
| Khrisna, M | 1 |
| Devault, KR | 1 |
| Talley, NJ | 2 |
| Achem, SR | 2 |
| Molina-Infante, J | 2 |
| Gisbert, JP | 1 |
| Chen, JW | 1 |
| Rubenstein, JH | 1 |
| Park, JY | 2 |
| Nguyen, N | 1 |
| Cheng, E | 4 |
| Gómez-Torrijos, E | 1 |
| García-Rodríguez, R | 1 |
| Castro-Jiménez, A | 1 |
| Rodríguez-Sanchez, J | 1 |
| Méndez Díaz, Y | 1 |
| Wilson, KS | 1 |
| Wang, DH | 3 |
| Huo, X | 3 |
| Yu, C | 3 |
| Sá, CC | 1 |
| Kishi, HS | 1 |
| Silva-Werneck, AL | 1 |
| Moraes-Filho, JP | 1 |
| Eisig, JN | 1 |
| Barbuti, RC | 1 |
| Hashimoto, CL | 1 |
| Navarro-Rodriguez, T | 1 |
| Levine, J | 1 |
| Lai, J | 1 |
| Edelman, M | 1 |
| Schuval, SJ | 1 |
| Tilakaratne, S | 1 |
| Day, A | 1 |
| Lemberg, D | 1 |
| Pham, TH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Controlled Trial Comparing Fluticasone Plus Omeprazole With Fluticasone Alone for Eosinophilic Esophagitis[NCT03781596] | Phase 4 | 100 participants (Anticipated) | Interventional | 2018-10-02 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for omeprazole and Eosinophilic Esophagitis
| Article | Year |
|---|---|
The outcome of patients with oesophageal eosinophilic infiltration after an eight-week trial of a proton pump inhibitor.
Topics: Adolescent; Adult; Aged; Endoscopy; Eosinophilia; Eosinophilic Esophagitis; Eosinophils; Female; Fol | 2013 |
Conservative long-term treatment of children with eosinophilic esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Child; Child, Preschool; Deglutition Disorders; Endoscopy; | 2012 |
17 other studies available for omeprazole and Eosinophilic Esophagitis
| Article | Year |
|---|---|
CD73
Topics: 5'-Nucleotidase; Animals; Cytokines; Eosinophilic Esophagitis; Homeostasis; Humans; Hyperplasia; Int | 2022 |
Dysphagia in a 34-Year-Old Woman.
Topics: Adult; Biopsy; Deglutition Disorders; Endoscopy, Digestive System; Eosinophilic Esophagitis; Esophag | 2020 |
Eosinophilic esophagoduodenitis with unusual response to omeprazole in a teenager.
Topics: Child; Endoscopy, Digestive System; Eosinophilic Esophagitis; Follow-Up Studies; Humans; Male; Omepr | 2021 |
Broad transcriptional response of the human esophageal epithelium to proton pump inhibitors.
Topics: Animals; Cell Line; Eosinophilic Esophagitis; Epithelial Cells; Esophageal Mucosa; Humans; Interleuk | 2021 |
In Esophageal Squamous Cells From Eosinophilic Esophagitis Patients, Th2 Cytokines Increase Eotaxin-3 Secretion Through Effects on Intracellular Calcium and a Non-Gastric Proton Pump.
Topics: Biological Transport; Boron Compounds; Calcium; Calcium Channel Blockers; Cell Line; Chemokine CCL26 | 2021 |
Eosinophilic Esophagitis: Treatment With Different Doses of Omeprazole in Children Under 16 Years.
Topics: Adolescent; Eosinophilic Esophagitis; Eosinophils; Female; Humans; Omeprazole; Prospective Studies | 2018 |
Minimally symptomatic patients with eosinophilic esophagitis should still be actively treated-CON.
Topics: Asymptomatic Diseases; Child; Clinical Decision-Making; Diet; Endoscopy; Eosinophilia; Eosinophilic | 2019 |
Letter: PPI-responsive oesophageal eosinophilia--from initial scepticism to consistent prospective data.
Topics: Endoscopy; Eosinophilic Esophagitis; Female; Humans; Male; Omeprazole; Proton Pump Inhibitors | 2014 |
Letter: PPI-responsive oesophageal eosinophilia--from initial skepticism to consistent prospective data; authors' reply.
Topics: Endoscopy; Eosinophilic Esophagitis; Female; Humans; Male; Omeprazole; Proton Pump Inhibitors | 2014 |
Response to empiric proton pump inhibitor therapy in patients with esophageal eosinophilia.
Topics: Endoscopy; Eosinophilic Esophagitis; Female; Humans; Male; Omeprazole; Proton Pump Inhibitors | 2014 |
Proton pump inhibitors decrease eotaxin-3 expression in the proximal esophagus of children with esophageal eosinophilia.
Topics: Adolescent; Anti-Inflammatory Agents; Cells, Cultured; Chemokine CCL26; Chemokines, CC; Child; Down- | 2014 |
The efficacy of step-down therapy in adult patients with proton pump inhibitor-responsive oesophageal eosinophilia.
Topics: Adolescent; Adult; Aged; Dose-Response Relationship, Drug; Endoscopy; Eosinophilic Esophagitis; Fema | 2016 |
JAK-STAT6 Pathway Inhibitors Block Eotaxin-3 Secretion by Epithelial Cells and Fibroblasts from Esophageal Eosinophilia Patients: Promising Agents to Improve Inflammation and Prevent Fibrosis in EoE.
Topics: Cell Line, Transformed; Chemokine CCL26; Chemokines, CC; Eosinophilic Esophagitis; Eosinophils; Epit | 2016 |
Eosinophilic esophagitis in patients with typical gastroesophageal reflux disease symptoms refractory to proton pump inhibitor.
Topics: Adolescent; Adult; Aged; Diagnosis, Differential; Eosinophilic Esophagitis; Female; Gastroesophageal | 2011 |
Omeprazole blocks eotaxin-3 expression by oesophageal squamous cells from patients with eosinophilic oesophagitis and GORD.
Topics: Adult; Cells, Cultured; Chemokine CCL26; Chemokines, CC; Enzyme-Linked Immunosorbent Assay; Eosinoph | 2013 |
Eosinophilic esophagitis and food impaction: an instructive case.
Topics: Adolescent; Androstadienes; Anti-Inflammatory Agents; Anti-Ulcer Agents; Deglutition Disorders; Drug | 2012 |
Omeprazole blocks STAT6 binding to the eotaxin-3 promoter in eosinophilic esophagitis cells.
Topics: Cell Culture Techniques; Chemokine CCL26; Chemokines, CC; DNA-Binding Proteins; Eosinophilic Esophag | 2012 |